Myriad Genetics (MYGN) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.99 +3.37%
Revenue Growth %: -7.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -7.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS sees a negative catalyst ahead for Nike: Here’s what to watch
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- Empress Royalty acquires Tongon gold stream for $62M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
